Cabaletta Bio Q4 2021 Earnings Report
Key Takeaways
Cabaletta Bio reported its Q4 and full year 2021 financial results. The company's DesCAARTes trial is progressing, and the MuSK-CAART IND application was cleared with Fast Track Designation granted by the FDA. The company ended the year with $122.2 million in cash on hand.
Observed a dose-dependent increase in DSG3-CAART persistence in cohort A3 relative to cohorts A1 and A2 throughout the 28 days following infusion.
Reported top-line biologic activity data from the two lowest dose cohorts in the DesCAARTes™ trial.
Progressing in cohort A5 of DesCAARTes™ trial.
MuSK-CAART Investigational New Drug (IND) application cleared and Fast Track Designation granted by the U.S. Food and Drug Administration (FDA).
Cabaletta Bio
Cabaletta Bio
Forward Guidance
Cabaletta expects that its cash and cash equivalents as of December 31, 2021, will enable it to fund its operating plan through the third quarter of 2023.